Equities research analysts expect Horizon Therapeutics PLC (NASDAQ:HZNP) to report $351.90 million in sales for the current fiscal quarter, according to Zacks. Three analysts have issued estimates for Horizon Therapeutics’ earnings, with the highest sales estimate coming in at $353.10 million and the lowest estimate coming in at $350.79 million. Horizon Therapeutics reported sales of $355.54 million in the same quarter last year, which would suggest a negative year-over-year growth rate of 1%. The business is scheduled to issue its next quarterly earnings results on Wednesday, February 26th.

On average, analysts expect that Horizon Therapeutics will report full year sales of $1.29 billion for the current year. For the next year, analysts forecast that the firm will report sales of $1.42 billion, with estimates ranging from $1.41 billion to $1.43 billion. Zacks’ sales averages are a mean average based on a survey of sell-side research analysts that that provide coverage for Horizon Therapeutics.

Horizon Therapeutics (NASDAQ:HZNP) last issued its quarterly earnings data on Wednesday, November 6th. The biopharmaceutical company reported $0.64 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.50 by $0.14. The company had revenue of $335.50 million for the quarter, compared to analyst estimates of $330.60 million. Horizon Therapeutics had a net margin of 5.25% and a return on equity of 27.71%. Horizon Therapeutics’s revenue was up 3.1% compared to the same quarter last year. During the same period last year, the company posted $0.65 earnings per share.

Several equities analysts recently issued reports on the stock. Stifel Nicolaus lifted their price objective on shares of Horizon Therapeutics from $35.00 to $40.00 and gave the company a “buy” rating in a report on Monday, December 16th. Cantor Fitzgerald lifted their price objective on shares of Horizon Therapeutics from $32.00 to $36.00 and gave the company an “overweight” rating in a report on Friday, November 8th. Goldman Sachs Group assumed coverage on shares of Horizon Therapeutics in a report on Wednesday, January 8th. They set a “neutral” rating and a $35.00 price objective on the stock. BMO Capital Markets lifted their price objective on shares of Horizon Therapeutics from $36.00 to $40.00 and gave the company an “outperform” rating in a report on Monday, December 16th. Finally, Morgan Stanley lifted their price objective on shares of Horizon Therapeutics from $32.00 to $38.00 and gave the company an “overweight” rating in a report on Monday, December 16th. Four research analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has given a strong buy rating to the stock. Horizon Therapeutics currently has an average rating of “Buy” and an average target price of $37.14.

In other Horizon Therapeutics news, EVP Brian K. Beeler sold 12,475 shares of the firm’s stock in a transaction that occurred on Tuesday, November 5th. The shares were sold at an average price of $30.02, for a total value of $374,499.50. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Timothy P. Walbert sold 84,886 shares of the firm’s stock in a transaction that occurred on Monday, January 6th. The shares were sold at an average price of $35.57, for a total transaction of $3,019,395.02. Following the completion of the sale, the chief executive officer now owns 987,991 shares of the company’s stock, valued at $35,142,839.87. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 126,888 shares of company stock valued at $4,413,598. 4.10% of the stock is owned by insiders.

Institutional investors and hedge funds have recently made changes to their positions in the business. Quadrant Capital Group LLC acquired a new stake in Horizon Therapeutics in the third quarter valued at approximately $66,000. Tower Research Capital LLC TRC boosted its stake in Horizon Therapeutics by 384.1% in the second quarter. Tower Research Capital LLC TRC now owns 3,389 shares of the biopharmaceutical company’s stock valued at $82,000 after acquiring an additional 2,689 shares in the last quarter. Bank of Montreal Can boosted its stake in Horizon Therapeutics by 45.7% in the second quarter. Bank of Montreal Can now owns 3,831 shares of the biopharmaceutical company’s stock valued at $92,000 after acquiring an additional 1,201 shares in the last quarter. Contravisory Investment Management Inc. acquired a new stake in Horizon Therapeutics in the fourth quarter valued at approximately $171,000. Finally, Point72 Asset Management L.P. acquired a new stake in shares of Horizon Therapeutics during the second quarter worth $125,000. Institutional investors own 88.24% of the company’s stock.

HZNP stock traded up $0.14 during trading on Thursday, hitting $38.40. 1,421,126 shares of the company’s stock traded hands, compared to its average volume of 1,787,856. The firm has a market capitalization of $6.86 billion, a P/E ratio of 20.98, a PEG ratio of 1.50 and a beta of 0.89. The business has a fifty day simple moving average of $34.63 and a two-hundred day simple moving average of $28.77. The company has a quick ratio of 2.23, a current ratio of 2.33 and a debt-to-equity ratio of 0.87. Horizon Therapeutics has a 1 year low of $20.05 and a 1 year high of $38.61.

About Horizon Therapeutics

Horizon Therapeutics Public Limited Company, a biopharmaceutical company, focuses on researching, developing, and commercializing medicines that address unmet treatment needs for rare and rheumatic diseases in the United States and internationally. Its orphan and rheumatology marketed medicines include KRYSTEXXA, a medicine for the treatment of uncontrolled gout; RAVICTI for use as a nitrogen-binding agent for chronic management of adult and pediatric patients; PROCYSBI for nephropathic cystinosis, a rare and life-threatening metabolic disorder; ACTIMMUNE for chronic granulomatous disease; RAYOS for the treatment of multiple conditions, rheumatoid arthritis; BUPHENYL tablets for oral administration and BUPHENYL powder for oral, nasogastric, or gastrostomy tube administration; and QUINSAIR, a formulation of the antibiotic drug levofloxacin for the management of chronic pulmonary infections due to Pseudomonas aeruginosa in adult patients with cystic fibrosis.

Featured Article: Inverted Yield Curve

Get a free copy of the Zacks research report on Horizon Therapeutics (HZNP)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Horizon Therapeutics (NASDAQ:HZNP)

Receive News & Ratings for Horizon Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Horizon Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.